On Oct 31, major Wall Street analysts update their ratings for $Arvinas (ARVN.US)$, with price targets ranging from $40 to $87.
Barclays analyst Peter Lawson maintains with a buy rating, and maintains the target price at $48.
Wells Fargo analyst Derek Archila maintains with a buy rating, and maintains the target price at $60.
TD Cowen analyst Tyler Van Buren maintains with a buy rating.
Oppenheimer analyst Matthew Biegler maintains with a buy rating, and maintains the target price at $40.
Truist Financial analyst Srikripa Devarakonda maintains with a buy rating.
Furthermore, according to the comprehensive report, the opinions of $Arvinas (ARVN.US)$'s main analysts recently are as follows:
The analyst noted that Arvinas' initial quarterly call was opportune, providing the company the platform to strategically position itself prior to a series of significant forthcoming events. The analyst expressed concerns that the TACTIVE-U data may not appear as compelling as the previous vepdeg + palbo results showcased at SABCS the prior year, suggesting that the combination may have set an unreasonably high benchmark due to drug-drug interaction (DDI) effects. A comparison to the EMBER-3 outcomes, anticipated to also be presented at SABCS, might be more appropriate. Further, the analyst mentioned that the EMBER-3 results could potentially affect the interpretation of the VERITAC-2 trial data, particularly if efficacy is confined to ESR1-mutants. Despite these considerations, the analyst maintains that VERITAC-2 could still pave the way for vepdeg's market entry, albeit with possibly a narrower commercial scope.
Here are the latest investment ratings and price targets for $Arvinas (ARVN.US)$ from 6 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
